Longevity & AgingResearch PaperOpen Access

Network meta-analysis ranks IL-23 inhibitors for Crohn's disease by speed, endoscopic healing and safety

A network meta-analysis of 14 trials compares guselkumab, mirikizumab, risankizumab and ustekinumab in Crohn's disease. Each drug shows a distinct efficacy-safety profile.

Saturday, November 14, 2026 0 views
Published in Ann Med
Stylized antibody molecules binding the IL-23 p19 subunit on a cytokine, glowing against a soft-lit intestinal tissue backdrop

Summary

This network meta-analysis compared four IL-23-pathway biologics (guselkumab, mirikizumab, risankizumab and ustekinumab) in adults with moderate-to-severe Crohn's disease. It pooled 14 randomized trials, with about 4,800 patients in induction and 3,600 in maintenance. Guselkumab had the strongest induction efficacy for clinical outcomes but carried the highest adverse-event risk versus placebo during maintenance. Risankizumab ranked best for endoscopic outcomes with a balanced safety profile. Mirikizumab had the lowest risk of serious adverse events in both phases. Ustekinumab showed more modest effects. Most comparisons are indirect and the certainty of evidence is often low, so the results can inform but not settle drug selection.

Detailed Summary

Crohn's disease is a chronic inflammatory bowel condition in which many patients fail to respond to biologics or lose response over time. Newer drugs that block IL-23 (the p19 inhibitors guselkumab, mirikizumab and risankizumab) are now alongside the older IL-12/23p40 blocker ustekinumab. Few head-to-head trials exist, so it is unclear how these agents compare. Earlier network meta-analyses mostly compared IL-23 inhibitors with other drug classes and often under-reported safety.

The authors searched PubMed, Embase and Cochrane CENTRAL (to May 2025), plus conference abstracts, for phase 2/3 randomized trials in adults with moderate-to-severe Crohn's disease. They included 14 trials: 4,834 patients in the induction phase (weeks 8–12) and 3,632 in maintenance (weeks 48–64). They ran a frequentist network meta-analysis of approved regimens, with a secondary analysis of all reported doses. Outcomes were clinical response and remission (CDAI-based), endoscopic response and remission (SES-CD-based), adverse events and serious adverse events. Treatments were ranked using SUCRA, and certainty was graded with CINeMA. Patients averaged 35–40 years old with a baseline CDAI around 300, and 50–70% had prior anti-TNF exposure.

During induction, guselkumab ranked first for clinical response and remission, followed by risankizumab, ustekinumab, mirikizumab and placebo. It was statistically superior to the other agents for clinical response. All agents beat placebo for clinical response. Risankizumab ranked highest for endoscopic outcomes. Guselkumab had the greatest adverse-event risk versus placebo in maintenance, and mirikizumab had the lowest serious adverse-event risk across both phases. Ustekinumab showed comparatively modest effects. The authors suggest guselkumab for rapid response, mirikizumab where safety is the priority, and risankizumab for balanced efficacy. They speculate that differences in Fc structure and IgG subclass may help explain the variation.

These findings could help clinicians tailor biologic choice to patient goals and risk tolerance. However, the evidence has important limits. Direct active-versus-active data come mainly from SEQUENCE (open-label), VIVID-1 and GALAXI, so most contrasts are indirect. Trials differed in design (treat-through versus re-randomized), assessment timing (ustekinumab at week 8, others at week 12) and outcome definitions. Safety outcomes were rated lower quality, with 92% of evaluations having some risk-of-bias concerns and no comparison reaching high certainty. Node-splitting found local inconsistency for guselkumab versus placebo in two analyses. Subgroup analyses of biologic-naive and biologic-experienced patients were not possible. The Fc-structure explanation is a hypothesis, not a tested finding.

Key Findings

  • Fourteen RCTs (4,834 induction, 3,632 maintenance patients) were pooled, comparing guselkumab, mirikizumab, risankizumab, ustekinumab and placebo in moderate-to-severe Crohn's disease.
  • Guselkumab ranked highest for induction clinical response and remission, superior to the other agents for clinical response, but had the greatest maintenance adverse-event risk versus placebo.
  • Risankizumab ranked highest for endoscopic outcomes while maintaining a balanced efficacy-safety profile.
  • Mirikizumab had the lowest risk of serious adverse events in both induction and maintenance phases.
  • Ustekinumab showed modest effects, and certainty of evidence was mostly low, with no high-certainty safety comparison.

Methodology

PRISMA-NMA-compliant systematic review (PROSPERO CRD420251072658) searching PubMed, Embase and CENTRAL through May 2025. Fourteen phase 2/3 RCTs were analyzed with a frequentist network meta-analysis (Stata), using SUCRA rankings, risk of bias (RoB 2) and CINeMA-based GRADE. Sensitivity analyses addressed time points, doses, re-randomization designs and one open-label head-to-head trial.

Study Limitations

Most comparisons are indirect, and the only direct head-to-head data come from a few trials, one of them open-label. Trials differed in design, assessment timing (week 8 for ustekinumab versus week 12 for others) and outcome definitions. Certainty was often low, especially for safety, and subgroup analyses by prior biologic exposure were not feasible. The Fc-structure explanation for the differences is speculative.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: